Inflammasomes in Liver Fibrosis
Semin Liver Dis 2017; 37: 119-127 DOI: 10.1055/s-0037-1601350Cell death and inflammation are two central elements in the development of liver fibrosis. Inflammasomes are intracellular multiprotein complexes expressed in both hepatocytes and nonparenchymal cells in the liver that are key regulators of inflammation and cell fate. They respond to cellular danger signals by activating caspase 1, releasing the proinflammatory cytokines IL-1β and IL-18, as well as initiating a novel pathway of programmed cell death termed “pyroptosis.” These processes can initiate and perpetuate an abnormal wound-healing response with the p...
Source: Seminars in Liver Disease - May 31, 2017 Category: Gastroenterology Authors: Alegre, Fernando Pelegrin, Pablo Feldstein, Ariel E. Tags: The Immune-Inflammation Connection Source Type: research
Immunotolerance in Liver Transplantation
Semin Liver Dis 2017; 37: 095-108 DOI: 10.1055/s-0037-1602762The burden of life-long immunosuppressive medication must be overcome if progress is to be made in long-term outcomes following transplantation. The liver exhibits intrinsic tolerogenic properties that contribute to a unique propensity toward spontaneous acceptance when transplanted. Hence, a proportion of liver transplant recipients develop a state of immunotolerance and display persistently normal allograft function despite the discontinuation of immunosuppression. However, this phenomenon remains elusive for the majority of recipients. Investigations performed...
Source: Seminars in Liver Disease - May 31, 2017 Category: Gastroenterology Authors: Mastoridis, Sotiris Martinez-Llordella, Marc Sanchez-Fueyo, Alberto Tags: The Immune-Inflammation Connection Source Type: research
Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus
Semin Liver Dis 2017; 37: 085-094 DOI: 10.1055/s-0037-1600522The treatment paradigm in hepatitis B virus is on the cusp of major development, with a multitude of novel agents undergoing testing for clinical efficacy. Such new immune therapies are urgently required for the treatment of chronic hepatitis B virus. The current direct antiviral therapies, although able to control viral replication and limit the progression to cirrhosis, require lifelong administration due to frequent viral rebound on treatment cessation, and immune modulation with interferon is only effective in a subpopulation of patients. Here the authors dis...
Source: Seminars in Liver Disease - May 31, 2017 Category: Gastroenterology Authors: Gill, Upkar S. Bertoletti, Antonio Tags: The Immune-Inflammation Connection Source Type: research
The Importance of Facts and the Role of Academic Publishers in Today's World —A Publisher's View
Semin Liver Dis 2017; 37: v-vi DOI: 10.1055/s-0037-1600103 Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents | Full text (Source: Seminars in Liver Disease)
Source: Seminars in Liver Disease - May 31, 2017 Category: Gastroenterology Authors: Schiff, Daniel Tags: Publisher's Note Source Type: research
Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?
Semin Liver Dis DOI: 10.1055/s-0037-1601349The availability of new direct antiviral agents to safely and effectively treat the hepatitis C virus represents a major advancement in the field of liver disease. Most patients achieve complete viral eradication sustained over time. In addition, the administration of these new agents is safe and does not require limitations when liver function is impaired. Some now expect the hepatitis C virus to be completely eradicated in a few years. However, not all data are positive. In April 2016, we published a cohort study suggesting that viral eradication with the new agents could be ass...
Source: Seminars in Liver Disease - April 7, 2017 Category: Gastroenterology Authors: Reig, Mar ía Boix, Loreto Mari ño, Zoe Torres, Ferran Forns, Xavier Bruix, Jordi Tags: Review Article Source Type: research
